We have previously published a systematic review and meta-analysis (SRMA) comparing low- versus high-dose rituximab (RTX) for the treatment of rheumatoid arthritis (RA), which showed no significant differences in primary efficacy outcomes between the two RTX schemes.
There were no significant differences in the primary outcomes and change in Health Assessment Questionnaire (HAQ), although the mean change in modified Total Sharp Score (mTSS) was 0.25 units (95 % CI, 0.01 to 0.49; P=0.04) higher in low-dose group at week 52. The author observed no significant difference in the median reduction in IgG levels between the study group.
Puerarin injection was effective for the treatment of diabetic peripheral neuropathy by improving the total effective rate, nerve conduction velocity that was decreased by diabetes, and improve the hemorheology index and also relatively safe clinically.
Diabetic peripheral neuropathy (DPN) is one of the most common neuropathies caused by diabetes mellitus (DM), with prevalence of 30-90%.
Acetyl-L-Carnitine (ALC) has a moderate effect in reducing pain on peripheral neuropathic pain (PNP) patients with acceptable safety. After treatment of ALC in diabetic subgroup presented a significant decreased in Visual Analogue Scale (VAS) scores and less significant reduction in VAS scores was observed in non-diabetic group compared with those receiving placebo.
Peripheral neuropathic pain (PNP) leads to an unpleasant experience due to lesion of peripheral nerves, which may be a result of a complication of diabetes mellitus, drug adverse effect, or other origins.